Uniqure N V Revenue Growth Rates (QURE), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Uniqure N v   (NASDAQ: QURE)
 

QURE's Revenue Growth by Quarter and Year

Uniqure N V 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/QURE/growth
https://api.csimarket.com/api/v1/companies/QURE/fundamentals
https://api.csimarket.com/api/v1/companies/QURE/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
QURE Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 5.20
2nd Quarter June 5.84
1st Quarter March 3.56
FY 14.60

QUREs Annual Revenue
Uniqure N V 's Revenue in the fiscal year 2025 $ 16.10 millions
Uniqure N V 's Revenue in the fiscal year 2024 $ 27.12 millions
Uniqure N V 's Revenue in the fiscal year 2023 $ 15.84 millions
Uniqure N V 's Revenue in the fiscal year 2022 $ 106.48 millions
Uniqure N V 's Revenue in the fiscal year 2021 $ 524.00 millions




QURE Revenue third quarter 2026 Y/Y Growth Comment
Uniqure N v reported Revenue rise of 40.43% year on year in the third quarter 2026, to $ 5.20 millions, this is lower than Uniqure N V 's recent average Revenue surge of 882.65%.

Looking into third quarter 2026 results within Major Pharmaceutical Preparations industry 35 other companies have achieved higher Revenue growth. While Uniqure N V ' s Revenue jump of 40.43% ranks overall at the positon no. 208 in the third quarter 2026.


QURE Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 40.43 %
2nd Quarter June 11.03 %
1st Quarter March 126.75 %
FY   -

Financial Statements
Uniqure N V 's third quarter 2026 Revenue $ 5.20 millions QURE's Income Statement
Uniqure N V 's third quarter 2025 Revenue $ 3.70 millions Quarterly QURE's Income Statement


QURE Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -11.03 %
2nd Quarter June 64.04 %
1st Quarter March -36.09 %
FY (Year on Year)   -


Back to QURE Growth rate Comparisons >> Back to QURE Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #36
Healthcare Sector #61
Overall #208

Revenue Y/Y Growth Statistics
High Average Low
30119.41 % 882.65 % -99.89 %
(Mar 31 2022)   (Sep 30 2022)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #36
Healthcare Sector #61
Overall #208
Revenue Y/Y Growth Statistics
High Average Low
30119.41 % 882.65 % -99.89 %
(Mar 31 2022)   (Sep 30 2022)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Uniqure N V 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
102073.57 % 2885.7 % -99.57 %
(Jun 30 2021)  


QURE's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Uniqure N V disclosed drop in Revenue from the second quarter by -11.03% to $ 5.20 millions, from $ 5.84 millions achived in the previous reporting period.

But that's not important problem, as Uniqure N V 's Revenue generally seem to plunge in this quarter.

Within Major Pharmaceutical Preparations industry 173 other companies have achieved higher Revenue quarter on quarter growth. While Uniqure N V 's Revenue growth quarter on quarter, overall rank is 3568.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #174
Healthcare Sector #502
Overall #3568
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #174
Healthcare Sector #502
Overall #3568
Revenue Q/Q Growth Statistics
High Average Low
102073.57 % 2885.7 % -99.57 %
(Jun 30 2021)  


QURE's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Uniqure N V disclosed drop in Revenue from the second quarter by -11.03% to $ 5.20 millions, from $ 5.84 millions achived in the previous reporting period.

But that's not important problem, as Uniqure N V 's Revenue generally seem to plunge in this quarter.

Within Major Pharmaceutical Preparations industry 173 other companies have achieved higher Revenue quarter on quarter growth. While Uniqure N V 's Revenue growth quarter on quarter, overall rank is 3568.


Uniqure N V 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025) 12 Months Ending (Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 18.67
Y / Y Revenue Growth (TTM) 30.24 %
Year on Year Revenue Growth Overall Ranking # 915
Seqeuential Revenue Change (TTM) 3.2 %
Seq. Revenue Growth (TTM) Overall Ranking # 2921


Cumulative Revenue growth Comment
Although Uniqure N V 's Annual Revenue growth year on year were below company's average 1329.26% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 30.24% year on year, from -10.44% in Mar 31 2026.

In the Healthcare sector 181 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 915, from total ranking in previous quarter at 2321.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 143
Healthcare Sector # 182
Overall # 915

Revenue TTM Y/Y Growth Statistics
High Average Low
13432.72 %
 1329.26 %
-86.88 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 143
Sector # 417
S&P 500 # 2921
Cumulative Revenue growth Comment
Although Uniqure N V 's Annual Revenue growth year on year were below company's average 1329.26% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 30.24% year on year, from -10.44% in Mar 31 2026.

In the Healthcare sector 181 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 915, from total ranking in previous quarter at 2321.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 143
Healthcare Sector # 182
Overall # 915

Revenue TTM Y/Y Growth Statistics
High Average Low
13432.72 %
1329.26 %
-86.88 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 143
Sector # 417
S&P 500 # 2921




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
QURE's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue drop for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Ptc Therapeutics inc 69.57%$ 69.571 millions
Seres Therapeutics Inc 68.95%$ 68.946 millions
Alamar Biosciences Inc 68.46%$ 68.458 millions
Carlsmed Inc 66.74%$ 66.736 millions
Corcept Therapeutics Inc63.97%$ 63.974 millions
Tarsus Pharmaceuticals Inc 63.92%$ 63.921 millions
Tg Therapeutics Inc 60.74%$ 60.743 millions
Therapeuticsmd Inc 60.59%$ 60.587 millions
Heartflow Inc 60.42%$ 60.425 millions
Glaukos Corp59.02%$ 59.021 millions
X4 Pharmaceuticals Inc58.64%$ 58.640 millions
Kiniksa Pharmaceuticals International Plc58.12%$ 58.121 millions
Envoy Medical Inc 57.14%$ 57.143 millions
Humacyte Inc 55.21%$ 55.208 millions
Butterfly Network Inc 53.45%$ 53.453 millions
Avita Medical Inc 53.05%$ 53.054 millions
Immunitybio inc 52.34%$ 52.338 millions
Axsome Therapeutics Inc 51.87%$ 51.873 millions
Yunhong Green Cti Ltd 51.28%$ 51.282 millions
Innovative Eyewear Inc 51.12%$ 51.123 millions
Strata Critical Medical Inc 50.27%$ 50.272 millions
Madrigal Pharmaceuticals Inc 50.13%$ 50.127 millions
Immucell Corporation49.91%$ 49.912 millions
Hims and Hers Health Inc 48.88%$ 48.877 millions
Maxcyte inc 48.66%$ 48.660 millions
Billiontoone Inc 47.43%$ 47.431 millions
Arcutis Biotherapeutics Inc 45.05%$ 45.052 millions
Zevra Therapeutics Inc 44.86%$ 44.864 millions
Xeris Biopharma Holdings Inc 44.16%$ 44.158 millions
Nephros Inc 43.60%$ 43.602 millions


About Uniqure N V Revenue Growth Rates (QURE), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Uniqure N V (CIK 1590560).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001104659-26-122367
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Uniqure N V’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.